About us
Nightingale Health is The Preventative Health Company.
Staying healthy is one of the top priorities in life. Our health has a profound impact on our quality of life, and it’s also strongly connected to the lives of those close to us.
Fortunately, up to 80 % of the common chronic diseases that shorten our healthy life can be prevented by simple actions in our daily lives. The difference in healthy years between the unhealthiest and the healthiest lifestyles can be as much as 40 years.
This is why Nightingale Health exists – to help prevent future diseases and maximize our healthy years.
We combine the power of our in-house developed, advanced blood analysis technology with unprecedented access to global health repositories and world-leading medical research. With this combination, we go beyond the traditional healthcare and wellbeing tools: We provide the scientific connection to multiple health and disease outcomes and the ability to predict future healthy years.
Understanding the future of our health and taking informed actions today is the key to lifelong health. We want to give people around the globe the power to be in charge of their health – and with it, help build a healthier world.
Milestones
2013
The company was founded based on scientific innovation: a blood test that can detect a wide variety of molecules from a single sample.
Read more about our proprietary technology.
2015
Our blood analysis technology was, and still is, widely used by world-leading scientists making novel findings in the field of chronic diseases.
Browse the list of publications.
2017
We obtained our first regulatory approvals, paving the way for healthcare use. Our quality management system was certified and we received a CE marking for the blood analysis technology.
2018
We kicked off a multi-year collaboration with the world’s largest biobank: UK Biobank.
Additionally, we won multiple awards including Health Innovation of the Year, Finnish Startup of the Year, and Best Health Tech Startup of the Year.
Read more about our collaboration with UK Biobank.
2019
We expanded to the United States by setting up a laboratory in Pittsburgh, Pennsylvania in collaboration with our shareholder PerkinElmer Inc.
Additionally, we became a private healthcare service provider and launched a pilot of our first direct-to-consumer service in Finland.
2020
We expanded to Japan in collaboration with our shareholder Mitsui & Co, Ltd. As part of the expansion, we set up an office and laboratory in the heart of Tokyo.
2021
Our Series B shares were listed on the Nasdaq Helsinki First North Growth Market, and we raised EUR 110 million in new funding to grow the company.
Visit our investor pages.
2022
We launched the direct-to-consumer service Livit by Nightingale Health which utilizes at-home blood collection.
Additionally, we announced our expansion into genetics and launched an international center of excellence for genomic data analysis.
Read our latest news.
Management team & founders
Teemu Suna
Chief Executive Officer, Founder
Jeffrey Barrett, PhD, FMedSci
Chief Scientific Officer
Antti Kangas
Chief Technology Officer, Founder
Tuukka Paavola
Chief Financial Officer
Salla Ruosaari, PhD
Chief R&D Officer
Satu Saksman
Chief Operating Officer
Minja Salmio
Chief Legal Officer
Pasi Soininen, PhD
Laboratory Director, Founder
Peter Würtz, PhD
Scientific Director, Founder
Board of directors
- Leena Niemistö, MD, PhD
- Tom Jansson
- Antti Kangas
- Olli Karhi, MD
- Lotta Kopra
- Timo Soininen
- Teemu Suna
Scientific advisory board
- Prof. John Danesh
- Prof. José Ordovás
- Prof. Eline Slagboom
- Prof. George Davey Smith